The combination of neoadjuvant pembrolizumab (Keytruda) combined with chemotherapy, followed by adjuvant pembrolizumab demonstrated significant overall-survival improvement in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback